Trial · NCT00669734
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
NCT00669734, Phase 1, Active not recruiting, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery. Trials, record NCT00669734. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00669734
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
- NCT number
- NCT00669734
- Status
- Active not recruiting
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Interventions
- Falimarev, Inalimarev, Laboratory Biomarker Analysis, Sargramostim
- First posted
- 2008-04-30
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT | 71 days | The descriptions and grading scales found in the Cancer Therapy Evaluation Program (CTEP) Active Version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for adverse events (AE) reporting. |
| Secondary | Mean number of positive cells per high power field in the pancreas biopsy specimen | Baseline | Compared between groups using the Fisher exact test. |
| Secondary | T cell proliferation | Up to 4 years | Analyzed by comparing pretreatment responses to post treatment responses for absolute differences and/or percent increase. |
| Secondary | Cytokine production | Up to 4 years | Analyzed by comparing pretreatment responses to post treatment responses for absolute differences and/or percent increase. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants3
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P30CA072720 | Cancer Center Support Grant | LIBUTTI, STEVEN K. | RUTGERS BIOMEDICAL AND HEALTH SCIENCES | NATIONAL CANCER INSTITUTE | 1997 to 2025 | NIH RePORTER |
| UM1CA186716 | Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics | JABBOUR, SALMA; LIU, GLENN | RBHS -CANCER INSTITUTE OF NEW JERSEY | NATIONAL CANCER INSTITUTE | 2014 to 2019 | NIH RePORTER |
| U01CA132194 | Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01) | DIPAOLA, ROBERT S. | RBHS -CANCER INSTITUTE OF NEW JERSEY | NATIONAL CANCER INSTITUTE | 2008 to 2013 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00669734
GET https://conductscience.org/api/trials/v1/NCT00669734/registered